VYNEHealthcareNano-Cap
VYNE Therapeutics Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for VYNE Therapeutics Inc. (VYNE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are VYNE insiders buying or selling?
VYNE Therapeutics Inc. insiders reported 13 open-market buys ($15.6M) and 5 sells ($9.1M) across 18 Form 4 filings — a net buying position of $6.4M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jan 16, 2025)
Total Form 4 filings
18
SEC EDGAR
Insider filers
6
Insider buys (13)
$15.6M
Insider sells (5)
$9.1M
Insider sentiment
Net buyingNet insider flow of $6.4M in net buying.
Recent VYNE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 16, 2025 | Patrick G Lepore | Director | Purchase | 15.0K | $2.92 | $43.8K |
| Nov 17, 2023 | Patrick G Lepore | Director | Purchase | 13.0K | $3.91 | $50.8K |
| Mar 22, 2023 | Patrick G Lepore | Director | Purchase | 20.0K | $2.48 | $49.7K |
| Mar 22, 2023 | Mutya Harsch | Chief Legal Officer and GC | Purchase | 10.0K | $2.50 | $25.0K |
| Dec 2, 2021 | Patrick G Lepore | Director | Purchase | 12.5K | $1.02 | $12.7K |
| Aug 26, 2021 | Patrick G Lepore | Director | Purchase | 12.5K | $1.60 | $20.0K |
| Aug 18, 2021 | Joseph Edelman | 10% Owner | Sale | 250.0K | $1.74 | $435.0K |
| Aug 17, 2021 | Joseph Edelman | 10% Owner | Sale | 250.0K | $1.84 | $460.0K |
| Aug 16, 2021 | Joseph Edelman | 10% Owner | Sale | 338.9K | $2.23 | $755.7K |
| May 27, 2021 | Patrick G Lepore | Director | Purchase | 12.5K | $3.60 | $45.0K |
| May 7, 2021 | Joseph Edelman | 10% Owner | Sale | 1.0M | $3.67 | $3.7M |
| Mar 16, 2021 | Patrick G Lepore | Director | Purchase | 12.5K | $7.41 | $92.6K |
| Feb 1, 2021 | Joseph Edelman | 10% Owner | Purchase | 4.2M | $2.37 | $10.0M |
| Dec 7, 2020 | Patrick G Lepore | Director | Purchase | 50.0K | $1.71 | $85.4K |
| Sep 9, 2020 | Andrew Saik | Chief Financial Officer | Purchase | 40.0K | $1.46 | $58.5K |
| Sep 9, 2020 | David Domzalski | President and CEO | Purchase | 75.0K | $1.38 | $103.6K |
| Jun 11, 2020 | Joseph Edelman | 10% Owner | Purchase | 2.7M | $1.85 | $5.0M |
| Jul 26, 2018 | Presidio Partners 2007 GP, L.P. | Other | Sale | 500.0K | $7.65 | $3.8M |
Showing the 18 most recent of 18 Form 4 filings for VYNE Therapeutics Inc..
Most active VYNE insiders
- Patrick G Lepore8 filings
- Joseph Edelman6 filings
- Andrew Saik1 filing
- David Domzalski1 filing
- Mutya Harsch1 filing
Ask anything about VYNE insider activity
Use Trabud's AI agent to query VYNE Therapeutics Inc.'s Form 4 history in plain English — "Show me VYNE CEO purchases this year" or compare it against any other ticker.
Open the AI agentVYNE insider trading FAQ
Are VYNE Therapeutics Inc. insiders buying or selling?
Across 18 SEC Form 4 filings, VYNE Therapeutics Inc. (VYNE) insiders reported 13 open-market purchases totaling $15.6M and 5 sales totaling $9.1M. That is a net buying position of $6.4M.
How many insiders trade VYNE stock?
6 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for VYNE Therapeutics Inc.. The most recent filing was accepted on Jan 16, 2025.
Where does Trabud get VYNE insider trading data?
All VYNE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.